4-苄氧基-哌啶盐酸盐 | 81151-68-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-苄氧基-哌啶盐酸盐
• 中文别名: 4-苄氧基哌啶；4-苄氧基哌啶盐酸盐
• 英文名称: 4-(benzyloxy)piperidine hydrochloride
• 英文别名: 4-phenylmethoxypiperidine;hydrochloride
• CAS: 81151-68-0
• 化学式: C₁₂H₁₇NO*ClH
• mdl: MFCD07368306
• 分子量: 227.734
• InChiKey: TYZNPXDFDHBMNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.49
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Benzyloxy-piperidine HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Benzyloxy-piperidine HCl
CAS number: 81151-68-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H17NO.ClH
Molecular weight: 227.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苄氧基-哌啶盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 33.0h， 生成 N1-(4-(4-benzyloxypiperidin-1-yl)-4-chloro-1,3,5-triazin-2-yl)benzene-1,3-diamine
  参考文献：
  名称：

  Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain

  摘要：

  Clinical human genetic studies have recently identified the tetrodotoxin (TTX) sensitive neuronal voltage gated sodium channel Nav1.7 (SCN9A) as a critical mediator of pain sensitization. Herein, we report structure-activity relationships for a novel series of 2,4-diaminotriazines that inhibit hNav1.7. Optimization efforts culminated in compound 52, which demonstrated pharmacokinetic properties appropriate for in vivo testing in rats. The binding site, of compound 52 on Nav1.7 was determined to be distinct from that of local anesthetics. Compound 52 inhibited tetrodotoxin-sensitive sodium channels recorded from rat sensory neurons and exhibited modest selectivity against the hERG potassium channel and against cloned and native tetrodotoxin-resistant sodium channels. Upon oral administration to rats, compound 52 produced dose- and exposure-dependent efficacy in the formalin model of pain.

  DOI：

  10.1021/jm200018k
• 作为产物：
  描述：

  4-(苄氧基)哌啶-1-羧酸叔丁酯 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 生成 4-苄氧基-哌啶盐酸盐
  参考文献：
  名称：

  Piperazine derivatives for the treatment of urinary incontinence and pain

  摘要：

  公开号：

  EP1849773B1

文献信息

• Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6
  作者：Yudao Shen、Magdalena M. Szewczyk、Mohammad S. Eram、David Smil、H. Ümit Kaniskan、Renato Ferreira de Freitas、Guillermo Senisterra、Fengling Li、Matthieu Schapira、Peter J. Brown、Cheryl H. Arrowsmith、Dalia Barsyte-Lovejoy、Jing Liu、Masoud Vedadi、Jian Jin

  DOI：10.1021/acs.jmedchem.6b01033

  日期：2016.10.13

  Well-characterized selective inhibitors of protein arginine methyltransferases (PRMTs) are invaluable chemical tools for testing biological and therapeutic hypotheses. Based on 4, a fragment-like inhibitor of type I PRMTs, we conducted structure–activity relationship (SAR) studies and explored three regions of this scaffold. The studies led to the discovery of a potent, selective, and cell-active dual

  蛋白质精氨酸甲基转移酶（PRMT）的特征明确的选择性抑制剂是测试生物学和治疗假设的宝贵化学工具。基于4，一种I型PRMTs的片段样抑制剂，我们进行了结构-活性关系（SAR）研究，并探索了该支架的三个区域。导致了有效的，选择性的发现的研究，并PRMT4和PRMT6，细胞活性双重抑制剂17（MS049）。与4相比，17在生化和细胞分析中显示PRMT4和PRMT6的效力大大提高。它对PRMT4和PRMT6的选择性高于其他PRMT和其他广泛的表观遗传修饰子和非表观遗传靶标。我们还开发了46（MS049N），在生化和细胞分析中不起作用，作为化学生物学研究的阴性对照。考虑到PRMTs可能重叠的底物特异性，17和46是用于解剖特定的生物学功能以及PRMT4和PRMT6在健康和疾病中异常调节的有价值的化学工具。
• CCR5 Antagonists as Anti-HIV-1 Agents. 1. Synthesis and Biological Evaluation of 5-Oxopyrrolidine-3-carboxamide Derivatives
  作者：Shinichi Imamura、Yuji Ishihara、Taeko Hattori、Osamu Kurasawa、Yoshihiro Matsushita、Yoshihiro Sugihara、Naoyuki Kanzaki、Yuji Iizawa、Masanori Baba、Shohei Hashiguchi

  DOI：10.1248/cpb.52.63

  日期：——

  A novel lead compound, N-3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl}-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), was identified as a CCR5 antagonist by high-throughput screening using [125I]RANTES and CCR5-expressing CHO cells. The IC50 value of 1 was 1.9 μM. In an effort to improve the binding affinity of 1, a series of 5-oxopyrrolidine-3-carboxamides was synthesized. Introduction of 3,4-dichloro substituents to the central phenyl ring (10i, IC50=0.057 μM; 11b, IC50=0.050 μM) or replacing the 1-methyl group of the 5-oxopyrrolidine moiety with a 1-benzyl group (12e, IC50=0.038 μM) was found to be effective for improving CCR5 affinity. Compound 10i, 11b, and 12e also inhibited CCR5-using HIV-1 envelope-mediated membrane fusion with IC50 values of 0.44, 0.19, and 0.49 μM, respectively.

  一种新型的铅化合物N-3-[4-(4-氟苯甲酰)piperidin-1-基]丙基}-1-甲基-5-氧代-N-苯基吡咯烷-3-羧酰胺（1）通过高通量筛选与[125I]RANTES和CCR5表达的CHO细胞被鉴定为CCR5拮抗剂。化合物1的IC50值为1.9 μM。为了提高化合物1的结合亲和力，合成了一系列5-氧代吡咯烷-3-羧酰胺。向中心苯环引入3,4-二氯取代基（10i，IC50=0.057 μM；11b，IC50=0.050 μM）或用1-苄基取代5-氧代吡咯烷部分的1-甲基基团（12e，IC50=0.038 μM）被发现有效提高了对CCR5的亲和力。化合物10i、11b和12e也分别以0.44、0.19和0.49 μM的IC50值抑制了CCR5使用的HIV-1包膜介导的膜融合。
• Piperidine derivatives, their preparation and pharmaceutical
  申请人：Synthelabo

  公开号：US04529730A1

  公开（公告）日：1985-07-16

  A piperidine derivative of the formula: ##STR1## wherein R represents a hydrogen atom, a (C.sub.1-4)alkyl, hydroxy(C.sub.1-4)alkyl, (C.sub.1-4)alkoxycarbonyl or benzyl radical, or a benzyl radical carrying a substituent selected from halogen atoms and (C.sub.1-4)alkoxy radicals, or the phenethyl or 3-phenylpropyl radical, and X represents one or more hydrogen or halogen atoms or (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy, trifluoromethyl or methylenedioxy radicals, or alternatively X forms with the phenyl nucleus a naphthyl radical, with the proviso that when R represents a hydrogen atom X is other than a hydrogen atom, are new compounds useful in therapy and, more particularly, as antidepressants.

  一种哌啶衍生物的化学式：##STR1## 其中R代表氢原子，(C.sub.1-4)烷基，羟基(C.sub.1-4)烷基，(C.sub.1-4)烷氧羰基或苄基基团，或携带卤素原子和(C.sub.1-4)烷氧基的苄基基团，或苯乙基或3-苯基丙基基团，并且X代表一个或多个氢原子或卤素原子或(C.sub.1-4)烷基，(C.sub.1-4)烷氧基，三氟甲基或二氧化甲基基团，或者X与苯环形成萘基基团，但是当R代表氢原子时，X不是氢原子。这些新化合物在治疗中有用，特别是作为抗抑郁剂。
• [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001025200A1

  公开（公告）日：2001-04-12

  A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  化合物式为（I）（其中R1是氢原子，可被取代的碳氢基团，可被取代的非芳香杂环基团，R2是可被取代的碳氢基团，可被取代的非芳香杂环基团，或R1和R2可以与A一起结合形成可被取代的杂环基团；A是N或N+ -R5 • Y-（R5是碳氢基团；Y-是反离子）；R3是可被取代的环烃基团或可被取代的杂环基团；n为0或1；R4是氢原子，可被取代的碳氢基团，可被取代的杂环基团，可被取代的烷氧基，可被取代的芳氧基，或可被取代的氨基，E是可被除氧基以外的基取代的二价脂肪烃基团；G1是键，CO或SO2；G2是CO，SO2，NHCO，CONH或OCO；J是甲基或氮原子；Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团；前提是当G2是OCO时，J是甲基，当另一个是键时，其中一个不是键，当G1是键时，Q和R中的每一个都没有被氧基团取代）或其盐具有强效的CCR5拮抗活性，并可用于人类各种HIV感染疾病（例如艾滋病）的治疗或预防。
• Cyclic amine compounds as CCR5 antagonists
  申请人：——

  公开号：US20030114443A1

  公开（公告）日：2003-06-19

  A compound of formula (I) (wherein R 1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R 2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R 1 and R 2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N + —R 5 .Y − (R 5 is a hydrocarbon group; Y − is a counter anion); R 3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R 4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G 1 is a bond, CO or SO 2 ; G 2 is CO, SO 2 , NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C 1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G 2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G 1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  化合物的式子 (I) (其中R1是氢原子、可以被取代的碳氢基团、可以被取代的非芳香族杂环基团，R2是可以被取代的碳氢基团、可以被取代的非芳香族杂环基团，或R1和R2可以与A结合形成可以被取代的杂环基团；A是N或N+—R5.Y−(R5是碳氢基团；Y−是反离子)；R3是可以被取代的环烃基团或可以被取代的杂环基团；n为0或1；R4是氢原子、可以被取代的碳氢基团、可以被取代的杂环基团、可以被取代的烷氧基、可以被取代的芳氧基，或可以被取代的氨基团；E是可以被取代的二价脂肪烃基团，该基团可以被除氧基团外的其他基团取代；G1是键、CO或SO2；G2是CO、SO2、NHCO、CONH或OCO；J是甲基或氮原子；Q和R中的每一个都是键或可以被取代的二价C1-3脂肪基团；但是当G2是OCO时，J是甲基；当Q和R中的一个是键时，另一个不是键；当G1是键时，Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性，可以用于治疗或预防人类各种HIV感染性疾病（例如艾滋病）。